semaglutide news october 2025 FDA Decisions Expected: - Prime Therapeutics glp-1 news october 1 2025

suspected adverse reactions should be reported via the MHRA Yellow Card scheme

For longer transport, gel packs specifically designed for pharmaceutical transport provide more reliable temperature control than improvised solutions

Data extraction The generic and brand names of GLP-1 RAs approved by the FDA were used to identify adverse events of GLP-1 RAs in the DRUG files, including exenatide (BYETTA, BYDUREON), liraglutide (VICTOZA, SAXENDA), dulaglutide (TRULICITY), lixisenatide (ADLYXIN, SOLIQUA), and semaglutide (OZEMPIC, RYBELSUS, WEGOVY)

This becomes especially important when you're in a calorie deficit and using GLP-1 therapy, as appetite suppression can sometimes make it harder to eat enough protein